Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents

Abstract

Vincristine pharmacokinetics were not age dependent in this paediatric population. Thus, we found no pharmacokinetic rationale for dose reduction in adolescents. The common practice of limiting the vincristine dose to 2.0 mg should be carefully reconsidered.